Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups.

BACKGROUND: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been...

Full description

Bibliographic Details
Authors: Rey-Bua, Beatriz, Cabrero, Monica, Bento, Leyre, Montoro, Juan, Bastos-Oreiro, Mariana, Parody, Rocio, Yanez, Lucrecia, Lopez-Godino, Oriana, Zanabili, Joud, Herrera, Pilar, Gutierrez, Gonzalo, Perez, Ariadna, Pinana, Jose L, Novelli, Silvana, Cortes, Maria, Sureda, Ana Maria, Caballero, Dolores, Garcia-Sancho, Alejandro Martin
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:INCLIVA
Repository:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p17028
Online Access:https://incliva.portalinvestigacion.com/publicaciones/17028
Access Level:Open access
Keyword:allogeneic stem cell transplantation
follicular lymphoma
non-Hodgkin lymphoma
transformed lymphoma
Description
Summary:BACKGROUND: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored. METHODS: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival. RESULTS: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31-67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2-9.6). CONCLUSIONS: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL.

Similar Items